Online inquiry

IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11509MR)

This product GTTS-WQ11509MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets FGFR3 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000142.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2261
UniProt ID P22607
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11509MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2272MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALXN1007
GTTS-WQ3570MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ14234MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RG-6107
GTTS-WQ4141MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BI-754091
GTTS-WQ10520MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY3002813
GTTS-WQ2847MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG-570
GTTS-WQ8327MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA HN-66000
GTTS-WQ5717MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CEA TCB
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW